Bio-Techne Corporation, trading under the symbol TECH on the NASDAQ, is a prominent player in the biotechnology sector. The company specializes in providing innovative tools and solutions for life sciences research and clinical diagnostics. Bio-Techne's competitors include companies like Thermo Fisher Scientific and Danaher Corporation, which also operate in the life sciences and diagnostics markets.
On February 4, 2026, Citigroup upgraded Bio-Techne's stock to a "Buy" rating, with the stock price at approximately $68.89. Citigroup also raised the price target from $70 to $80, indicating confidence in the company's future performance. This upgrade suggests that Citigroup sees potential for growth and value in Bio-Techne's stock.
Bio-Techne recently held its Q2 2026 earnings call, as highlighted by Seeking Alpha. The call provided valuable insights into the company's financial performance and strategic initiatives. Investors and stakeholders closely follow these calls to gauge the company's current position and future outlook. The earnings call is a crucial event for understanding Bio-Techne's revenue, profit margins, and any significant developments or challenges faced during the quarter.
Currently, TECH is priced at $68.77, reflecting a notable increase of 6.41%, or $4.14. The stock has shown volatility, with a daily range between $61.70 and $69.92. Over the past year, TECH has reached a high of $79.28 and a low of $46.01. This fluctuation indicates the dynamic nature of the stock market and the factors influencing Bio-Techne's stock price.
Bio-Techne's market capitalization is approximately $10.72 billion, with a trading volume of 3.59 million shares. This market cap reflects the company's size and value in the biotechnology sector. The trading volume indicates the level of investor interest and activity in Bio-Techne's stock, which can impact its price movements.
